Calidi Biotherapeutics Inc (CLDI)

May 22, 2025, 7:43 AM EDT - 16 days ago

Innovation In Indexing: Why Passive ETFs Matter

ELFY INVN OWNB PEVC SPY TOV XIDV

Apr 25, 2025, 8:00 AM EDT - 6 weeks ago

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Apr 18, 2025, 8:06 AM EDT - 7 weeks ago

When Domestic ETF Bias Meets Intentional International Exposure

IVV MADE NRSH RSHO SPLG VOO

Apr 16, 2025, 1:44 PM EDT - 7 weeks ago

Global X Launches 2 Domestic-Focused ETFs

Apr 16, 2025, 9:30 AM EDT - 7 weeks ago

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

Mar 31, 2025, 4:30 PM EDT - 2 months ago

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 28, 2025, 9:00 AM EDT - 2 months ago

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 10, 2025, 8:00 AM EDT - 3 months ago

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Feb 28, 2025, 9:00 AM EST - 3 months ago

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Feb 24, 2025, 8:00 AM EST - 3 months ago

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Jan 29, 2025, 8:00 AM EST - 4 months ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

Jan 28, 2025, 8:00 AM EST - 4 months ago

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Jan 10, 2025, 4:30 PM EST - 5 months ago

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Jan 10, 2025, 8:30 AM EST - 5 months ago

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Jan 8, 2025, 4:01 PM EST - 5 months ago

Calidi Biotherapeutics Announces Proposed Public Offering

Nov 15, 2024, 4:05 PM EST - 7 months ago

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Nov 14, 2024, 8:30 AM EST - 7 months ago

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Nov 12, 2024, 5:29 PM EST - 7 months ago

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 25, 2024, 9:00 AM EDT - 8 months ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

Oct 24, 2024, 8:30 AM EDT - 8 months ago

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Oct 23, 2024, 8:31 AM EDT - 8 months ago

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Oct 18, 2024, 11:00 PM EDT - 8 months ago

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Oct 18, 2024, 8:45 AM EDT - 8 months ago

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GRRR

Aug 13, 2024, 5:37 PM EDT - 10 months ago

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 2, 2024, 9:00 AM EDT - 11 months ago

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Jul 29, 2024, 9:00 AM EDT - 11 months ago

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

Jul 18, 2024, 8:00 AM EDT - 11 months ago

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Jul 16, 2024, 8:00 AM EDT - 11 months ago

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Jul 5, 2024, 4:15 PM EDT - 1 year ago

Calidi to Effect Reverse Stock Split

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Jun 11, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

May 31, 2024, 8:51 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

May 17, 2024, 9:00 AM EDT - 1 year ago

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

UMAC

May 14, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

May 1, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

Apr 19, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Apr 16, 2024, 8:31 AM EDT - 1 year ago

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024

Mar 15, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Feb 12, 2024, 7:00 AM EST - 1 year ago

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Jan 8, 2024, 7:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Dec 13, 2023, 7:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Nov 14, 2023, 4:05 PM EST - 1 year ago

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 3, 2023, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)

Sep 13, 2023, 5:50 AM EDT - 1 year ago

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Sep 11, 2023, 4:05 PM EDT - 1 year ago

First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments